key: cord-0691862-au8vahwe
authors: Steers, Nicholas J.
title: Humoral response to SARS-CoV-2 in hemodialysis patients
date: 2021-06-09
journal: Kidney Int Rep
DOI: 10.1016/j.ekir.2021.05.036
sha: 0491145783c55df53ca49dcaaed9bae11dfce249
doc_id: 691862
cord_uid: au8vahwe

nan

Patients with end stage renal disease (ESRD) require maintenance dialysis while waiting for a kidney transplant or if not eligible for a transplant. Even with significant improvements in hemodialysis and peritoneal dialysis there is still a high mortality rate.

Infections are one of the major causes of death in renal patients requiring dialysis due to an impaired innate and adaptive immune system induced by uremia 1 

Immune cell dysfunction and inflammation in end-stage renal disease

Aspects of immune dysfunction in end-stage renal disease

Impaired immune responses and antigen-specific memory CD4+ T cells in hemodialysis patients

Hepatitis B virus vaccine immune response and mortality in dialysis patients: a meta-analysis

Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus

Decline and loss of anti-SARS-CoV-2 antibodies in kidney transplant recipients in the 6 months following SARS-CoV-2 infection

IgG SARS-CoV-2 antibodies persist at least for 10 months in patients on hemodialysis

Neutralizing Antibody Responses After SARS-CoV-2 Infection in End-Stage Kidney Disease and Protection Against Reinfection